Renzhong Xiao

Dr. Renzhong Xiao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZFZhaosong Feng
Zhaosong Feng
YGYuyang Gu
Yuyang Gu
MYMengping Yuan
Mengping Yuan
RXRenzhong Xiao
Renzhong Xiao
ZFZhenghua Fei
Zhenghua Fei
Objective: Clinical trials have become essential for driving the development of medicine. However, little is known about the current status of clinical trials on liposomes in children’s anticancer therapy (LCAT). This study aimed to synthesize current finding from clinical trials of LCAT in ClinicalTrials.gov. Methods: A cross-sectional descriptive study of clinical trials on LCAT was conducted, using studies registered on ClinicalTrials.gov through December 30, 2021. Results: A total of 74 eligible trials were identified, accounting for 4.8% (74/1552) of all trials on liposomes for cancer therapy. Among these trials, 70 (94.6%) were interventional trials, and the remaining 4 (5.4%) were observational trials. Of the 70 interventional trials, 63 (90.0%) were for treatment, 48.6% were involving unlabeled allocations, 30.0% were randomized, 52.9% were single group assignment, 71.4% were without masking, 28.6% were Phase 3 trials, 30.0% were Phase 1 trials, and 24.3% were Phase 2 trials. Furthermore, 17 liposomal drugs for 123 types of cancer were investigated in the interventional trials, and these were mainly focused on organic chemicals (43/70, 61.4%). Of these cancers, the highest proportion was leukemia (15.4%), followed by lymphoma (9.8%) and ovarian cancer (8.9%). Conclusion: High quality, adequately powered, masked, appropriately sized, and randomized clinical trials represent the critical priorities for conducting a high-quality clinical trial. However, most of these trials for LCAT were non-randomized, single group assignment, and non-blinded interventional trials of small scale, with various eligibility criteria and outcome measures. Our analysis highlights the need for improvement in the completeness of study designs curated on clinicalTrials.gov. We urge for decision-makers to avoid adopting entrenched positions about the study design of cancer clinical trials to avoid this problem. As such, tackling the problematic challenges related to cancer and designing efficient trials for cancer requires developing and applying new approaches and multiple strategies.

1 February 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
STShiyang Tang
Shiyang Tang
RXRenzhong Xiao
Renzhong Xiao
ZZZhaowu Zeng
Zhaowu Zeng
JXJianyuan Xi
Jianyuan Xi
Psoriasis is a chronic, relapsing inflammatory skin disease. Topical treatments are the primary choice for up to 80% of psoriasis patients; however, their effectiveness is often limited by poor penetration into the skin. Nanocarriers represent a promising advancement in drug delivery systems by enhancing bioavailability and tissue penetration and reducing the frequency of dosing. This study conducted a narrative review and analyzed the characteristics of clinical trials registered on ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) that investigated the use of nanocarriers for psoriasis treatment. The findings indicate that the proportion of registered randomized controlled trials (RCTs) focusing on nanocarriers for psoriasis treatment is exceedingly limited, comprising only 0.2% (11 out of 5338) of all registered RCTs related to psoriasis treatment. Among these 11 RCTs, six types of nanocarriers were identified: microemulsion/nanoemulsion, chitosan nanoparticles, liposomes, ethosomes, micelles, and niosomes. Five trials reported complete or partial outcomes using the Psoriasis Area and Severity Index (PASI) as the primary efficacy measure. However, many trials had incomplete baseline and follow-up PASI data. Studies have shown that encapsulating APIs within nanocarriers generally yields a more significant reduction in PASI scores than administering empty nanocarriers. Additionally, no study has directly compared nanocarriers with traditional formulations. The APIs used in these RCTs primarily comprised lipophilic drugs. In conclusion, although nanocarriers for psoriasis treatment demonstrate significant potential, they continue to face challenges, including incomplete regulatory frameworks, difficulties in large-scale production, and high production costs.

1 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JYJianyue Ying
Jianyue Ying
RXRenzhong Xiao
Renzhong Xiao
LXLili Xu
Lili Xu
MYMei Yan
Mei Yan
Background. Opioid‐induced constipation (OIC) has become increasingly prevalent with the rise of prescription opioid use, particularly in patients with advanced illnesses. Existing literature suggests that transcutaneous electrical nerve stimulation (TENS) could be applied to treat cancer pain and reduce OIC incidence. However, there need to be more systematic review studies on the effectiveness of TENS in treating OIC. Objective. In order to fill the gap of TENS in treating OIC in current knowledge, we have conducted a systematic review and network meta‐analysis. Methods. The comprehensive computer retrieval PubMed, Embase, Cochrane, China National Knowledge Infrastructure (CNKI), Chinese Biomedical (CBM), and Wanfang Database were used to collect literature for relevant studies of TENS treatment of OIC, in accordance with the standard of literature filtering, data extraction, and quality evaluation. The data were meta‐analysed using ReviewManager 5.3 software recommended by Cochrane. Results. A total of 180 pieces of literature were yielded through original search. Based on the inclusion and exclusion criteria, a total of 9 articles were included in this study. Our analysis of seven studies has revealed that TENS (28.18%) significantly reduces the incidence rate of OIC compared to control (52.45%) (I2 = 57%, P = 0.03; OR = 0.66 (95% CI, 0.53 to 0.82), Z = 3.70, P < 0.01). The results of two studies indicated that TENS significantly improved the quality of life compared to the control group (i.e., treatment‐as‐usual only) (I2 = 80%, P = 0.03; OR = −1.91; 95% CI, −2.54 to −1.29, Z = 6.00, P < 0.01). Conclusion. The administration of TENS therapy holds the potential to mitigate the occurrence of OIC and augment the quality of life for individuals suffering from cancer. Particularly, TENS therapy proves to be appropriate for propagation within community and domestic environments. Nevertheless, advanced clinical randomized controlled trials of superior quality are necessary to authenticate the comprehensive clinical efficiency and safety of this therapy. Further investigation is indispensable to comprehend its mechanism in greater detail and establish the optimum therapeutic strategy.

8 April 2025 in Chinese Journal of Analytical Chemistry
Verified
Journal Article
Open access
MYMei Yan
Mei Yan
GLGuanping Lai
Guanping Lai
RXRenzhong Xiao
Renzhong Xiao